Project Sc(y)lla Characterization: SARS-Cov-2 Large-scale Longitudinal Analyses on the comparative safety and effectiveness of treatments under evaluation for COVID-19 across an international observational data network
=============
<h2>PLEASE NOTE: All results are preliminary and subject to change</h2>

<hr class="w-100" style="border-top: black 1px solid;">

<h3>Terms of Use:</h3>
<p>These results are being shared as part of OHDSI's open science community efforts to characterize disease natural history of COVID-19, for the purposes of enabling collaborative research within the community.  Synthesis of the results and interpretation of the findings is underway and manuscripts are being prepared.  All manuscripts must be reviewed and approved by all co-authors and data partner contributors prior to submission.  Until final publication, all results are to be considered preliminary and subject to change, and may only be used under the terms of use of the respective data partner contributors.</p>

**Objectives:**<br>
The aim of this study is to characterize all emerging drug therapies used in COVID-19 treatment.<br>
<br>
Specifically, the study aims to chararacterize:<br>
<br>
<ol>
  <li>Treatments administered during hospitalization and prior to intensive services</li>
  <li>Treatments administered during hospitalization after initiating intensive services</li>
  <li>Treatments administered after COVID-19 positive testing or diagnosis in outpatient setting without prior hospitalization</li>
</ol>
**Resources:**<br>
- The study protocol is available <a href="https://www.ohdsi.org/wp-content/uploads/2020/05/OHDSI-SCYLLA-PLE-COVID-effectiveness-protocol-v1.0-final-with-appendix.pdf" target="_blank">here</a>
- All analytic code is availble at <a href="https://github.com/ohdsi-studies/ScyllaCharacterization" target="_blank">GitHub</a>

**Cohort Diagnostics:**<br>
- <a href="#">TBD</a>
